Xpovio (selinexor) for Myeloma

Overview
Xpovio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory multiple myeloma in adults who have received at least four prior therapies. Xpovio is also known by its drug name, selinexor.

Xpovio is a member of a class of drugs called nuclear export inhibitors. Xpovio is believed to work by blocking the nuclear export protein XPO1 to cause cancer cell death.

How do I take it?
Prescribing information states that Xpovio is given orally as a tablet. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Xpovio lists common side effects that include nausea, fatigue, decreased appetite, weight loss, diarrhea, vomiting, constipation, and difficulty breathing.

Serious side effects listed for Xpovio include low blood cell counts, stomach and intestinal damage, nerve damage, and fetal harm.

For more details about this treatment, visit:

Xpovio — Karyopharm
https://www.xpovio.com

Xpovio (selinexor) — International Myeloma Foundation
https://www.myeloma.org/xpovio-selinexor